The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML
Official Title: A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients With Relapsed or Refractory AML or CMML
Study ID: NCT03922100
Brief Summary: The purpose of this study is to explore safety, tolerability, including the maximum tolerated dose and the recommended Phase II dose (RP2D), and antitumor activity of NMS-03592088 in adult patients with relapsed or refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML).
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Centre Hospitalier du Mans, Le Mans, , France
Centre Hospitalier Universitaire de Nantes (CHU de Nantes) - Hotel-Dieu, Nantes, , France
Hôpital Saint-Antoine, Paris, , France
CHU Hopitaux de Bordeaux - Hôpital Haut-Lévêque, Pessac, , France
Centre Hospitalier Lyon-Sud, Pierre-Bénite, , France
ASST Papa Giovanni XXIII, Bergamo, BG, Italy
ASST Grande Ospedale Metropolitano Niguarda, Milano, MI, Italy
Istituto Clinico Humanitas, Rozzano, MI, Italy
Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi, Bologna, , Italy
ASST Spedali Civili di Brescia, Brescia, , Italy
Azienda Ospedaliero-Universitaria Careggi, Firenze, , Italy
Fondazione IRCCS Policlinico San Matteo, Pavia, , Italy
Fondazione Policlinico Universitario Agostino Gemelli, Roma, , Italy
Ospedale Le Molinette, Torino, , Italy
Catalan Institute of Oncology (ICO), Badalona, , Spain
Hospital San Pedro de Alcántara, Cáceres, , Spain
Hospital Universitari i Politècnic La Fe, Valencia, , Spain
Name: Alessandro Rambaldi, MD
Affiliation: ASST Papa Giovanni XXIII
Role: PRINCIPAL_INVESTIGATOR